Literature DB >> 19876039

Asenapine.

Herbert Y Meltzer1, Argyris Dritselis, Uma Yasothan, Peter Kirkpatrick.   

Abstract

In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19876039     DOI： 10.1038/nrd3027

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  16 in total

Review 1.  Bipolar disorder.

Authors:  R H Belmaker
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

2.  Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.

Authors:  Simona Volpi; Steven G Potkin; Anil K Malhotra; Louis Licamele; Christian Lavedan
Journal:  J Clin Psychiatry       Date:  2009-06       Impact factor: 4.384

3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

4.  Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.

Authors:  Jari Tiihonen; Kristian Wahlbeck; Jouko Lönnqvist; Timo Klaukka; John P A Ioannidis; Jan Volavka; Jari Haukka
Journal:  BMJ       Date:  2006-07-06

5.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

Authors:  Jari Tiihonen; Jouko Lönnqvist; Kristian Wahlbeck; Timo Klaukka; Leo Niskanen; Antti Tanskanen; Jari Haukka
Journal:  Lancet       Date:  2009-08-22       Impact factor: 79.321

6.  Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

Authors:  Steven G Potkin; Miriam Cohen; John Panagides
Journal:  J Clin Psychiatry       Date:  2007-10       Impact factor: 4.384

7.  Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia.

Authors:  Olivia Frånberg; Charlotte Wiker; Monica M Marcus; Asa Konradsson; Kent Jardemark; Björn Schilström; Mohammed Shahid; Erik H F Wong; Torgny H Svensson
Journal:  Psychopharmacology (Berl)       Date:  2007-10-17       Impact factor: 4.530

8.  Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.

Authors:  M Shahid; G B Walker; S H Zorn; E H F Wong
Journal:  J Psychopharmacol       Date:  2008-02-28       Impact factor: 4.153

9.  Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors.

Authors:  C L Broekkamp; J S De Graaf; A M van Delft
Journal:  Arzneimittelforschung       Date:  1990-05

Review 10.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Authors:  S Leucht; D Arbter; R R Engel; W Kissling; J M Davis
Journal:  Mol Psychiatry       Date:  2008-01-08       Impact factor: 15.992
View more
  6 in total

1.  Neuroleptic malignant syndrome after exposure to asenapine: a case report.

Authors:  Niku Singh; Thomas N Wise
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

2.  Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.

Authors:  Rongyin Qin; Yingzhu Chen; Ming Li
Journal:  Neuropharmacology       Date:  2013-08-14       Impact factor: 5.250

3.  Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.

Authors:  Jun Gao; Ming Li
Journal:  Behav Brain Res       Date:  2013-10-05       Impact factor: 3.332

4.  The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder.

Authors:  Maurizio Pompili; Paola Venturini; Marco Innamorati; Gianluca Serafini; Ludovica Telesforo; David Lester; Roberto Tatarelli; Paolo Girardi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-06       Impact factor: 2.570

5.  Asenapine, a new sublingual atypical antipsychotic.

Authors:  R Balaraman; Hardik Gandhi
Journal:  J Pharmacol Pharmacother       Date:  2010-01

6.  Androgen suppresses testicular cancer cell growth in vitro and in vivo.

Authors:  Hideo Nakagawa; Takashi Ueda; Saya Ito; Takumi Shiraishi; Hidefumi Taniguchi; Naruhiro Kayukawa; Hiroyuki Nakanishi; So Ushijima; Motohiro Kanazawa; Terukazu Nakamura; Yoshio Naya; Fumiya Hongo; Kazumi Kamoi; Koji Okihara; Osamu Ukimura
Journal:  Oncotarget       Date:  2016-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.